News Agile Therapeutics, Inc.

Equities

AGRX

US00847L3087

Delayed OTC Markets Other stock markets 11:55:17 2024-04-19 am EDT			5-day change	1st Jan Change
0.368 ^USD	-0.54%		+1.07%	-81.13%

Mar. 28	Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024
Mar. 28	Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024	Mar. 28
Agile Therapeutics: Q4 Earnings Snapshot	Mar. 28	AQ
Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M	Mar. 28	MT
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update	Mar. 28	AQ
Agile Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from S&P TMI Index	Mar. 27	CI
Agile Therapeutics Announces Delisting from Nasdaq	Mar. 25	AQ
Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from NASDAQ Composite Index	Mar. 24	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024	Mar. 21	AQ
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024	Mar. 20	AQ
North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
Maxim Downgrades Agile Therapeutics to Hold From Buy	Mar. 18	MT
Agile Therapeutics Inc. Completes Pay-Off the Remainder of its Debt Facility	Mar. 14	CI
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution	Mar. 13	AQ
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds	Feb. 22	AQ
Top Premarket Gainers	Feb. 22	MT
Agile Therapeutics, Inc. Announces Senior Secured Term Loan Credit Facility of Up to $35.0 Million	Feb. 15	CI
Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year Ended December 31, 2023	Feb. 15	CI
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update	Feb. 15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Agile Therapeutics, Inc.

Equities

AGRX

US00847L3087

Summary

Filters